Novartis' leading hypertension drug, Diovan®, gains marketing approval in Japan
25-Sep-2000 -
Basel, 22 September 2000 - Novartis announced today that it has received marketing approval from
the Japanese Ministry of Health and Welfare for Diovan® (valsartan), its highly selective
angiotension receptor blocker (ARB), for the treatment of hypertension (high blood pressure). The
company ...
acute myocardial infarction
agrochemicals
AstraZeneca
+8